Visit booth 307 to learn how Covalon is
creating a new standard for compassionate IV care technology
designed to help protect patients from infections, pain, and
trauma
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), an advanced medical technologies company, today
announced its participation in the 2023 Annual Oley Foundation
Conference being held in St. Louis, Missouri from Tuesday, June 27
to Friday, June 30, 2023. Patients, caregivers, healthcare
providers, and advocates looking for more compassionate care
solutions for those living with intravenous therapies should visit
Covalon at booth 307 to learn more about Covalon’s unique position
to provide “apology-free” dressings that are gentle on skin.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230627972227/en/
IV fluid line secured to the forearm with
IV Clear®, a soft dual-antimicrobial silicone IV securement
dressing offered by Covalon. (Photo: Business Wire)
“There is no reason why patients living with daily or frequent
IV-line care need to live with the pain, discomfort, and worry that
can come with receiving IV therapy,” said Ron Hebert, Senior Vice
President, Marketing, Covalon. “For those relying on parenteral
nutrition, their IV is a lifeline, but it can also be a direct line
to infection, pain, and trauma. At Covalon, we’re committed to
improving the patient experience with comfortable and flexible
dressings and vascular access line guards that help protect the
line, while providing patients with the flexibility and freedom
they deserve.”
Stable and safe intravenous access with a central venous
catheter is an absolute requirement for delivery of total
parenteral nutrition (TPN). Dressings and line guards play a
critical role in protecting patients from an increased risk of
infection that comes with TPN (long term and sometimes for life)
and keeping the vulnerable skin surrounding line sites healthy and
comfortable.
Not all IV dressings are made equal. Due to differences in
adhesive materials and active ingredients, IV dressings may not
provide patients the protection from infection intended and cause
medical adhesive related skin injuries (MARSI) surrounding the IV
insertion site, an area vulnerable to pathogen entry.
The two most common adhesive components used in IV dressings are
acrylic and silicone:
- Acrylic adhesives are known to be incredibly strong due
to their tackiness. Acrylic can perform well when it comes to
holding, fixing, and gripping - but it can be incredibly traumatic
to the patient’s skin. Acrylic can also be time consuming to move,
requiring healthcare providers to use solvents and scrapers.
- Soft silicone dressings are tacky enough to adhere to
the surrounding skin, while being gentle enough to allow for
minimized trauma during dressing changing.
If a patient has delicate skin and will be wearing an IV
securement dressing for long periods of time, a silicone dressing
is best for minimizing pain and trauma.
Covalon’s IV Clear dressing is the world’s only dual
antimicrobial silicone adhesive vascular access dressing. Its
features include:
- Chlorhexidine and silver embedded into the entire surface of
the dressing provide broad spectrum protection.
- Silicone adhesive helps to maintain skin integrity and keeps
patients comfortable.
- Complete transparency allows for visualization and easy daily
assessment of the site and surrounding skin.
Covalon’s other IV-related solutions include:
- CovaClear® IV – utilizes soft silicone adhesive technology to
help protect patients from skin injuries, but does not incorporate
antimicrobials, for use with patients who either don't require or
cannot tolerate antimicrobials.
- VALGuard® - a transparent, environmental barrier designed to
protect catheter hubs and line connections from external
contaminants and gross contamination, including body fluids and
other secretions. It incorporates a quick-release pull strip for
fast access to infusion hubs and for easy removal.
The 2023 Annual Oley Foundation Conference
The Oley Foundation aims to enrich the lives of those living
with home intravenous (IV) nutrition or tube feeding through
advocacy, education, community, and innovation. The conference
brings together clinicians, patients, and industry to facilitate
knowledge sharing on tube feeding and IV nutrition. Covalon
representatives will be available to meet with participants on
site. To make an appointment, please contact Ron Hebert, SVP
Marketing, at rhebert@covalon.com.
Conference details
Dates: Tuesday, June 27 – Friday, June 30, 2023
Venue: Hyatt Regency St. Louis at The Arch (315 Chestnut Street,
St. Louis, Missouri 63102)
Registration: https://oley.org/event/Oley2023
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon’s
solutions, visit www.covalon.com or follow Covalon on LinkedIn,
Facebook, Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon’s name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which is available on the Company’s
profile at www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230627972227/en/
To learn more about Covalon:
Brian Pedlar, CEO, Covalon Technologies Ltd.
Email:bpedlar@covalon.com Phone:905.568.8400 x 233
Toll-Free:1.877.711.6055 Website:https://covalon.com/
Twitter:@covalon
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 12 2024 まで 1 2025
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 1 2024 まで 1 2025
